Khiron Life Sciences Corp

Healthcare CA KHRN

NoneCAD
0.00(0%)

Last update at 2024-04-29T17:29:13.988597Z

Day Range

LowHigh

52 Week Range

0.040.17

LowHigh

Fundamentals

Previous Close -
Market Cap9.30M
VolumeNone
P/E Ratio-
Dividend Yield-%
EBITDA-16.40602M
Revenue TTM16.14M
Revenue Per Share TTM0.09
Gross Profit TTM 6.37M
Diluted EPS TTM-0.17

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Income before tax	-33.59400M	-23.94991M	-36.35503M	-19.72796M	-4.53529M
Minority interest	-	-	-	-	-
Net income	-33.12900M	-24.03889M	-36.37778M	-19.80654M	-4.53529M
Selling general administrative	23.99M	28.41M	35.91M	20.19M	3.31M
Selling and marketing expenses	-	-	-	-	-
Gross profit	6.37M	7.01M	2.44M	0.30M	-
Reconciled depreciation	1.11M	1.17M	0.94M	0.34M	-
Ebit	-20.02600M	-23.60499M	-35.97963M	-18.62518M	-4.51750M
Ebitda	-32.03400M	-22.43750M	-36.64132M	-19.55841M	-
Depreciation and amortization	-	-	-	-	-
Non operating income net other	-	-	-	-	-
Operating income	-19.78700M	-23.60499M	-37.57985M	-19.89633M	-4.51750M
Other operating expenses	-	-	-	-	-
Interest expense	0.45M	0.00000M	0.00000M	0.00000M	0.00000M
Tax provision	-0.46500M	0.09M	0.02M	0.08M	-
Interest income	-	-	-	-	-
Net interest income	-0.44500M	-	-	-	-
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	-0.46500M	0.09M	0.02M	0.08M	-
Total revenue	12.79M	8.02M	9.58M	0.89M	-
Total operating expenses	32.58M	31.62M	47.16M	20.79M	4.52M
Cost of revenue	6.42M	1.01M	7.15M	0.59M	-
Total other income expense net	-13.36100M	-0.34492M	1.22M	0.17M	-0.01779M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	-33.12900M	-24.03889M	-36.37778M	-19.80654M	-4.53529M
Net income applicable to common shares	-33.12900M	-24.03889M	-36.37778M	-19.80654M	-4.53529M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Total assets	42.27M	73.18M	81.91M	40.35M	2.90M
Intangible assets	0.87M	15.13M	15.55M	2.01M	0.00097M
Earning assets	-	-	-	-	-
Other current assets	-	14.28M	1.97M	0.08M	-
Total liab	8.95M	9.95M	11.87M	14.81M	0.70M
Total stockholder equity	33.33M	63.23M	70.04M	25.54M	2.19M
Deferred long term liab	-	-	-	-	-
Other current liab	1.89M	-	-	0.18M	0.21M
Common stock	146.45M	137.08M	121.29M	39.83M	4.29M
Capital stock	146.45M	137.08M	121.29M	39.83M	-
Retained earnings	-116.81200M	-83.68299M	-59.96373M	-23.58595M	-3.77941M
Other liab	0.52M	0.90M	0.89M	5.86M	-
Good will	4.08M	4.11M	4.35M	4.64M	-
Other assets	-	-	1.34M	0.15M	-
Cash	8.92M	8.17M	9.17M	14.93M	1.81M
Cash and equivalents	-	-	-	-	-
Total current liabilities	7.72M	7.34M	8.44M	6.60M	0.70M
Current deferred revenue	-	-	-	-	-
Net debt	-	-	-	-	-
Short term debt	-	-	-	0.16M	-
Short long term debt	1.52M	1.08M	1.01M	0.16M	-
Short long term debt total	-	-	-	-	-
Other stockholder equity	3.69M	9.83M	8.71M	9.30M	1.68M
Property plant equipment	13.56M	17.52M	15.86M	9.62M	0.24M
Total current assets	23.77M	36.42M	44.81M	23.93M	2.65M
Long term investments	-	-	-	-	-
Net tangible assets	28.39M	43.98M	50.14M	18.90M	2.19M
Short term investments	-	0.00000M	27.56M	3.95M	-
Net receivables	2.88M	4.58M	4.24M	4.17M	0.29M
Long term debt	0.70M	1.71M	2.55M	2.35M	-
Inventory	9.45M	8.34M	0.96M	0.24M	-
Accounts payable	4.31M	6.26M	7.43M	6.44M	0.45M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	-	-	-	-	-
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	-	-	37.10M	16.42M	-
Deferred long term asset charges	-	-	-	-	-
Non current assets total	18.50M	36.76M	37.10M	16.42M	-
Capital lease obligations	-	-	-	-	-
Long term debt total	-	-	-	-	-

Breakdown	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Investments	-2.08600M	27.56M	-23.05105M	-3.94955M	-3.94955M
Change to liabilities	-2.83200M	-1.86119M	0.85M	0.67M	0.85M
Total cashflows from investing activities	-2.08600M	24.87M	-31.97643M	-9.21997M	-0.29034M
Net borrowings	-0.10700M	-0.55519M	-1.27270M	11.59M	11.59M
Total cash from financing activities	10.89M	12.17M	57.00M	37.59M	5.41M
Change to operating activities	-0.36000M	1.39M	-1.94902M	0.00536M	-0.08581M
Net income	-33.12900M	-24.03889M	-36.37778M	-19.80654M	-4.53529M
Change in cash	-12.72600M	12.30M	-5.66884M	13.20M	2.17M
Begin period cash flow	21.65M	9.34M	15.01M	1.81M	0.00496M
End period cash flow	8.92M	21.65M	9.34M	15.01M	1.81M
Total cash from operating activities	-20.40000M	-24.53235M	-30.07485M	-14.77391M	-2.90955M
Issuance of capital stock	11.00M	12.94M	53.14M	0.91M	-
Depreciation	1.11M	1.17M	0.94M	0.34M	0.00008M
Other cashflows from investing activities	-	-	-	-	-
Dividends paid	-	-	-	-	-
Change to inventory	-1.44000M	-2.06976M	-0.70045M	-0.18122M	-0.18122M
Change to account receivables	2.31M	0.61M	-1.38182M	0.83M	-0.34431M
Sale purchase of stock	0.00000M	-0.21239M	-	-	-
Other cashflows from financing activities	-	0.58M	2.69M	2.69M	2.69M
Change to netincome	13.94M	0.28M	8.55M	3.37M	1.21M
Capital expenditures	1.74M	2.69M	6.09M	3.83M	0.29M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	-2.32700M	-1.93891M	-3.18238M	1.33M	-
Stock based compensation	2.32M	5.72M	9.37M	-	-
Other non cash items	-1.08200M	-5.52745M	-0.84705M	-	-
Free cash flow	-22.14400M	-27.22550M	-36.16960M	-18.59974M	-

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company	Change (CAD)	Price (CAD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
KHRN Khiron Life Sciences Corp	- -%	-	-	-	0.58	0.34	0.61	-0.3471
RX Biosyent Inc.	0.05 0.36%	14.00	19.10	15.85	3.96	4.11	3.31	11.03
DB Decibel Cannabis Company Inc	- -%	0.12	-	8.67	0.67	1.20	0.99	17.75
ZYUS ZYUS Life Sciences Corporation	- -%	0.50	-	-	108.48	4.41	140.29	-4.258
LSL LSL Pharma Group Inc.	0.005 1.59%	0.32	20.75	-	1.88	1.89	2.85	10.19

Reports Covered

View All

Profile

Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe. It operates through Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and cannabidiol (CBD) medical cannabis. It also operates a network of health centers and satellite clinics under the ILANS and Zerenia brands; develops CBD-based cosmeceutical products under the Kuida brand name; and operates Zerenia clinic in Medellin and Peru. Khiron Life Sciences Corp. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Khiron Life Sciences Corp

500 Burrard Street, Vancouver, BC, Canada, V6C 2B5

705 527 3564
https://khiron.ca

Key Executives

Name	Title	Year Born
Dr. Alvaro Francisco Torres	Co-Founder, CEO & Director	1979
Ms. Franziska Katterbach	Pres of Khiron Europe	NA
Mr. Swapan Kakumanu ACA, ACWA, CGA	Corp. Sec.	1970
Ms. Helen Bellwood A.C.A.	Interim Chief Financial Officer	NA
Mr. Manuel Buendia	VP of Operations	NA
Mr. Luis Chavez	Country Mang. of Mexico	NA
Mr. Marco Algorta	Country Mang. of Uruguay	NA
Mr. Juan Diego Alvarez	VP of Regulations	1985

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.